REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 VectorPRESS RELEASE PR Newswire Jul. 31, 2019, 07:07 AM网页链接 $Regenxbio(RGNX)$